SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 424B5
Document Type: 424B5
Date Filed: 2025-12-09
Accession Number: 0001213900-25-119671
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025119671/ea0268926-424b5_synergy.htm

Chunk 10 of 23
Word Count: 1465
Character Count: 9319

Document Content:

Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The date of this prospectus is December 9, 2025. TABLE OF CONTENTS ABOUT THIS PROSPECTUS ii PROSPECTUS SUMMARY 1 RISK FACTORS 7 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 8 USE OF PROCEEDS 9 THE SECURITIES WE MAY OFFER 10 DESCRIPTION OF CAPITAL STOCK 11 DESCRIPTION OF DEBT SECURITIES 14 DESCRIPTION OF STOCK WARRANTS 20 DESCRIPTION OF SUBSCRIPTION RIGHTS 21 DESCRIPTION OF UNITS 22 FORMS OF SECURITIES 23 PLAN OF DISTRIBUTION 25 LEGAL MATTERS 28 EXPERTS 28 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES 29 ADDITIONAL INFORMATION 30 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 31 Synergy CHC Corp. is referred to herein as “Synergy,” “the Company,” “we,” “us” and “our,” unless the context indicates otherwise.

You may only rely on the information
contained in this prospectus and the accompanying prospectus or that we have referred you to. We have not authorized anyone to provide
you with different information. This prospectus and any prospectus supplement do not constitute an offer to sell or a solicitation of
an offer to buy any securities other than the securities offered by this prospectus and the prospectus supplement. This prospectus and
any prospectus supplement do not constitute an offer to sell or a solicitation of an offer to buy any securities in any circumstances
in which such offer or solicitation is unlawful. Neither the delivery of this prospectus or any prospectus supplement nor any sale made
hereunder shall, under any circumstances, create any implication that there has been no change in our affairs since the date of this prospectus
or such prospectus supplement or that the information contained by reference to this prospectus or any prospectus supplement is correct
as of any time after its date.

ABOUT THIS PROSPECTUS

This prospectus is part of
a registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a “shelf” registration
process. Under this shelf registration process, we may from time to time offer and sell, in one or more offerings, any or all of the securities
described in this prospectus, separately or together, up to an aggregate offering price of $100 million. This prospectus provides you
with a general description of our securities being offered. When we issue the securities being offered by this prospectus, we will provide
a prospectus supplement that will contain specific information about the terms of that offering. The prospectus supplement may also add,
update or change information contained in this prospectus. You should read both this prospectus and any prospectus supplement together
with additional information described under the heading “Additional Information” and “Incorporation of Certain Information
by Reference.”

PROSPECTUS SUMMARY

The following summary highlights
some information from this prospectus. It is not complete and does not contain all of the information that you should consider before
making an investment decision. You should read this entire prospectus, including the “Risk Factors” section on page 7
and the disclosures to which that section refers you, the financial statements and related notes and the other more detailed information
appearing elsewhere or incorporated by reference into this prospectus before investing in any of the securities described in this prospectus.

Our Company

We are a provider of consumer health care, beauty, and lifestyle products.
Our current brand portfolio consists of two marquee brands, FOCUSfactor, a clinically-tested brain health supplement (this study
was performed independently and is not related to any FDA-approved investigational new drug (IND) application) that has been shown
to improve memory, concentration and focus, and Flat Tummy, a lifestyle and wellness brand that provides a suite of nutritional products
to help women achieve their nutrition and weight management goals. For the year ended December 31, 2024, FOCUSfactor represented
88% of our net revenue and Flat Tummy was 12%. For the nine months ended September 30, 2025, FOCUSfactor represented 86% of our net revenue
and Flat Tummy represented 14%. Our products are sold through some of the nation’s leading club, mass drug, and other retailers
such as Costco, Amazon.com, Walmart, Walgreens, CVS, BJ’s Wholesale Club, Publix Supermarkets, The Vitamin Shoppe, Target.com, H-E-B,
Meijer, and Albertson’s. Additionally, we have expanded into Canada and the United Kingdom.

We built our brand portfolio
through strategic acquisitions. We acquired the FOCUSfactor brand in January 2015 for cash consideration of $6.0 million, including
earnout. In November 2015, we acquired our second marquee brand, Flat Tummy, for AUD 10.0 million (approximately $7.0 million),
using a mix of cash and stock. Our capital structure following the acquisitions of our key brands in 2015 has been highly levered, and
our focus has been on paying our debt and, as a result, we do not have the resources to grow our business. We have grown our FOCUSfactor
brand from 3 SKUs at acquisition to over 34 SKUs, and our Flat Tummy Brand from 1 SKU to 13 SKUs. We use the term SKU, or stock-keeping unit,
to refer to a product with a unique UPC (Universal Product Code), which is the barcode used to identify products.

Our growth from 2022 to the present was driven by expanded distribution
of our FOCUSfactor product line to some of our major retailers, such as Costco, CVS and Walmart, among others. This expansion included
SKUs within our FOCUSfactor vision line as well as focus and energy Ready-to-Drink (RTD). As a result, net revenue for the year ended
December 31, 2024 was $34.8 million, a decrease of $8 million, or 19%, compared to net revenue for the year ended December 31,
2023 of $42.8 million. Net revenue for the nine months ended September 30, 2025 was $24.3 million, a decrease of $0.3 million, or
1% compared to net revenue of $24.6 million for the nine months ended September 30, 2024. FOCUSfactor net revenue decreased 2% from $21.3
million for the nine months ended September 30, 2024 to $20.8 million for the nine months ended September 30, 2025. FOCUSfactor net revenue
for the year ended December 31, 2024 was $30.8 million, a 17.0% decrease from FOCUSfactor net revenue for the year ended December 31,
2023 of $37.2 million. During the nine months ended September 30, 2025 we also had revenue from a license agreement of $2.9 million
related to expansion in selected foreign markets, which we anticipate to be an ongoing source of revenue.

Our Brands

Our flagship brand, FOCUSfactor, is a brain health nutritional supplement
with over 24 years of history and a clinically-tested formula (this study was performed independently and is not related to
any FDA-approved IND application) comprised of a proprietary blend of key brain supporting ingredients along with vitamins, minerals,
and other nutrients. We believe FOCUSfactor is the only product in its category whose entire formula has been shown to support memory,
concentration and focus. Our FOCUSfactor brand consists of over 34 SKUs and is sold primarily through leading retailers in the United States,
including Costco, Walmart, Amazon.com, Walgreens, CVS, Meijer, and Albertson’s in addition to selling direct to consumer through
the FOCUSfactor website. Across three of our key partners, we have increased the number of SKUs sold through the retailer from the single
SKU available at the beginning of our relationship in 2015 or 2016. In addition, we have increased our presence in retail locations for
these key partners, resulting in a significant increase in points of distribution, being the number of SKUs multiplied by the number of
retail locations for each retailer. We have also expanded the brand internationally into Canada (2020), the UK (2023) and we anticipate
being in Mexico in the fourth quarter of 2025 and in Taiwan, Australia and Asia in 2026.

FOCUSfactor has expanded into
the beverage market with its focus plus energy RTD. According to Zion Research in January 2024, the beverage market is large
($176 billion in 2022) and growing (projected 8.6% CAGR covering eight years from 2022 through 2030) with an expanding range
of functional benefits such as energy, hydration, cognition/focus, weight loss, gut health and immunity. Examples such as Celsius and
Beyond Raw offer dual-benefit products that deliver fat burning plus energy while C4 Smart Energy and FocusAid deliver focus plus
energy. Additionally, consumers are looking for not only refreshing drinks but health perks such as zero sugar and low-calorie drinks.
This consumer shift in preferences towards more functional benefits can be seen in the evolution of the energy RTD category where originally
competitors like Red Bull and Monster delivered conventional energy, then the category offered more performance energy products with added
vitamins and amino acids in products such as Reign and C4 Performance to products with more natural energy characteristics and then to
the dual-benefit energy products that we see today.